Cargando…
Validation of a preclinical model for assessment of drug efficacy in melanoma
The aim of personalized medicine is to improve our understanding of the disease at molecular level and to optimize therapeutic management. In this context, we have developed in vivo and ex vivo preclinical strategies evaluating the efficacy of innovative drugs in melanomas. Human melanomas (n = 17)...
Autores principales: | Delyon, Julie, Varna, Mariana, Feugeas, Jean-Paul, Sadoux, Aurélie, Yahiaoui, Saliha, Podgorniak, Marie-Pierre, Leclert, Geoffroy, Dorval, Sarra Mazouz, Dumaz, Nicolas, Janin, Anne, Mourah, Samia, Lebbé, Céleste |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914342/ https://www.ncbi.nlm.nih.gov/pubmed/26909610 http://dx.doi.org/10.18632/oncotarget.7541 |
Ejemplares similares
-
Correction: Validation of a preclinical model for assessment of drug efficacy in melanoma
por: Julie, Delyon, et al.
Publicado: (2016) -
A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors
por: Louveau, Baptiste, et al.
Publicado: (2019) -
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019) -
Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019) -
A Reliable Method for the Selection of Exploitable Melanoma Archival Paraffin Embedded Tissues for Transcript Biomarker Profiling
por: Lebbe, Celeste, et al.
Publicado: (2012)